Jason Butler
Stock Analyst at Citizens
(4.64)
# 190
Out of 5,084 analysts
144
Total ratings
52.74%
Success rate
39.92%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $11.31 | +67.99% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $62.76 | +46.59% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $6.42 | +86.92% | 8 | Oct 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $107.68 | -11.78% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $28.45 | -1.58% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $26.42 | +40.07% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $15.21 | +156.49% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $3.68 | +63.04% | 11 | Jun 12, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $39.19 | +155.17% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $32.24 | +17.87% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $66.08 | +18.05% | 16 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.65 | +108.09% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.82 | +4.71% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $917.69 | -23.61% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $11.00 | +200.00% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $9.58 | -6.05% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.89 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $10.62 | +78.91% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $3.59 | +513.67% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.52 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $18.82 | +223,023.05% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $14.28 | +712.32% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.34 | +107.60% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.62 | - | 1 | Dec 2, 2020 |
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $11.31
Upside: +67.99%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $62.76
Upside: +46.59%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $6.42
Upside: +86.92%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $107.68
Upside: -11.78%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $28.45
Upside: -1.58%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $26.42
Upside: +40.07%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $15.21
Upside: +156.49%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.68
Upside: +63.04%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $39.19
Upside: +155.17%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $32.24
Upside: +17.87%
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $66.08
Upside: +18.05%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.65
Upside: +108.09%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.82
Upside: +4.71%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $917.69
Upside: -23.61%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $11.00
Upside: +200.00%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $9.58
Upside: -6.05%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.89
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $10.62
Upside: +78.91%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $3.59
Upside: +513.67%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.52
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $18.82
Upside: +223,023.05%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $14.28
Upside: +712.32%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.34
Upside: +107.60%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.62
Upside: -